Kwality Pharmaceuticals Ltd — Important, 19-05-2026: Company Update

Kwality Pharmaceuticals reported strong financial results, with full-year revenue at ₹503 Cr and net profit at ₹67 Cr. The company achieved EU-GMP certification for four out of five manufacturing units and serves over 70 countries globally. Key strategic initiatives include advancing its Kwalipoietin biosimilar into clinical trials for a potential launch in the coming financial year. Expansion is underway with a new hormones facility and increased capacity for biologics and oncology, supported by ongoing R&D and bioequivalence programs to penetrate regulated markets. The company targets ₹650 Cr revenue and ₹100 Cr net profit for the next financial year.